Selective monoclonal versus polyclonal antibodies for induction of immunosuppression in lung recipients [3]

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 1, 2002, Pages 103-

  Gerbase, Margaret W ^a   De Perrot, Marc ^a   Spiliopoulos, Anastase ^a   Nicod, Laurent P ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN; CYCLOSPORIN A; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; POLYCLONAL ANTIBODY; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

BLOOD CELL COUNT; CYTOMEGALOVIRUS; FOLLOW UP; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LETTER; LUNG TRANSPLANTATION; LYMPHOCYTE; PRIORITY JOURNAL; RECIPIENT; THROMBOCYTOPENIA; VIRUS ACTIVATION; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; BLOOD PLATELETS; GLOBULINS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; RECOMBINANT FUSION PROTEINS;

EID: 0036331720     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.125695     Document Type: Letter

References (4)

1. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients
2. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody
3. Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus
4. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody